Loading
A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05168566 by Teligene US, with 99 participants planned, started 2022-09-01 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/